Interpace Biosciences Inc
interpace.comWhat Do They Do?
Provides molecular diagnostic tests and pathology services to physicians, hospitals and clinics to assess thyroid cancer risk and guide care for patients with indeterminate biopsies.
10-K for FY2025, filed Mar 30, 2026We are a company that provides esoteric molecular diagnostic testing and pathology services to aid physicians in their evaluation of cancer…View ↗
Customer Category Types of Customers Nature of Services Clinical services ● Hospitals ● Physicians ● Cancer Centers ● Clinics ● Commercial…View ↗
Our clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. We…View ↗
We currently have two commercialized molecular diagnostic tests in the marketplace: ThyGeNEXT®, an oncogenic mutation panel that helps…View ↗
How Do They Make Money?
The company performs proprietary tests and bills Medicare, other insurers, or direct-billing clients after test results are completed, reviewed, and released.
10-K for FY2025, filed Mar 30, 2026
$38.7M
-
10-K for FY2025, filed Mar 30, 2026
$38.7M ↗
Who Are Their Customers?
Physicians, hospitals and clinics, and commercial laboratories and pathology groups use the tests. Sales run through direct and indirect channels, including collaborations with laboratory services companies.
10-K for FY2025, filed Mar 30, 2026Customer Category Types of Customers Nature of Services Clinical services ● Hospitals ● Physicians ● Cancer Centers ● Clinics ● Commercial…View ↗
Our clinical services’ customers consist primarily of physicians, hospitals, cancer centers, commercial laboratories, pathology groups and…View ↗
Our sales and marketing efforts consist of both direct and indirect sales channels with efforts focused predominantly in the United States.…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 63 cents of every revenue dollar as net income in FY2025 and turned 14 cents into free cash flow.
10-K for FY2025, filed Mar 30, 2026
$4.1MView ↗
10-K for FY2025, filed Mar 30, 2026
$24.6MView ↗
10-K for FY2025, filed Mar 30, 2026
$5.5MView ↗
How Are They Changing?
Growing. Revenue grew 4.7x in 4 years, from $8.2M in FY2021 to $38.7M in FY2025, about 47% a year.
Narrowed focus to thyroid cancer
The older report described gastrointestinal and endocrine assays alongside thyroid tests; the latest centers efforts on thyroid cancer tests after PancraGEN was discontinued.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Mar 30, 2026Our primary goal is to become a leader in providing high quality and dependable personalized medicine with exceptional growth. Our strategy…View ↗
We are a company that provides esoteric molecular diagnostic testing and pathology services to aid physicians in their evaluation of cancer…View ↗
Who Do They Compete With?
Competes with Veracyte, Quest Diagnostics, and Sonic Healthcare USA
10-K for FY2025, filed Mar 30, 2026Specifically, in regard to our thyroid diagnostic tests, Veracyte, Inc., or Veracyte, has a molecular thyroid nodule cancer diagnostic test…View ↗
Loading...
